GeoVax Labs, Inc.
The biotechnology company, which develops human immunotherapies and vaccines against infectious diseases and cancer, announced today that the U.S. Patent and Trademark Office has issued patent No. 11278607 to GeoVax, following its patent application No. 16 / 068,527 entitled “Compositions and Methods for Generating “an immune response to a tumor-associated antigen.
The claims granted by the patent generally cover GeoVax’s vector platform for tumor-associated antigens and virus-like particles (VLPs) from a modified Vaccinia Ankara (MVA) viral vector expression and include GeoVax’s Mucin 1 (MUC1) Tumor Immunoassin Candidate Immunoassay .
The company uses its GV-MVA-VLP ™ vaccination platform to express abnormal, aberrant glycosylated forms of the cell surface-associated MUC1 protein associated with a wide range of cancers, including breast, colon, ovary, prostate, pancreas, and pancreas. .
CEO David Dodd commented: “The initial results with our MVA-VLP-MUC1 immunotherapy candidates were encouraging and we recently started an IND-activated animal study with Dr. Pinku Mukherjee at the University of North Carolina at Charlotte to determine the optimal course. define and schedule the vaccination to define a protocol that can be evaluated in a Phase 1 clinical trial.
“We believe that our MVA vector platform is well suited for the development of therapeutic cancer vaccines based on the expression of tumor-associated antigens such as MUC1 and cyclin B1, among others.”
GOVX shares began trading Tuesday at 29 cents, or 18.6%, at $ 1.85.
Add Comment